Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market

There's a new battle brewing between Eli Lilly (LLY) and Novo Nordisk (NVO) — and it could add to the projected $200 billion market for weight-loss drugs. Both companies have made a name for themselves in developing injections that mimic the GLP-1 hormone to improve feelings of satiety and blood sugar markers. But pills could be a major inflection point…